Board of Directors

The Board of Directors are responsible for the guidance, risk management and strategic direction of Hudson Institute.

Dr Robert (Bob) Edgar

BEcon (Hons), PhD (Ohio State), FAICD

Dr Edgar has extensive experience in financial services, including 25 years at ANZ Bank where he retired as Deputy Chief Executive Officer in 2009. He is also a director on the boards of Djerriwarrh Securities, Linfox Armaguard Pty Ltd and Transurban Ltd.
Special responsibilities: Board Chair

Professor Christina Mitchell


Prof Mitchell is the Academic Vice-President and Dean of the Faculty of Medicine, Nursing and Health Sciences at Monash University. Prof Mitchell is a physician-scientist, specialising in clinical haematology. In 2011, she was the first woman appointed Dean of Medicine among the group of eight universities in Australia. In 2015, Prof Mitchell was inducted into the Victorian Honour Roll of Women for her leadership as the Dean and also received the Lemberg Medal which is awarded annually to a distinguished Australian biochemist.  In 2015, Prof Mitchell became a member of the Australian Academy of Health and Medical Sciences.

Ms Maria Trinci

Ms Maria Trinci BA/BComm, CA

Ms Trinci is a partner with KPMG, and has been specialising in financial services since 2000. In 2012, she was admitted to the partnership and is the head of Capital Markets for KPMG Australia as well as the Head of Digital for the Audit, Assurance and Risk Consulting Business. Ms Trinci has worked in London, Edinburgh, Glasgow and New York. She is Chair of the Cancer Council Victoria board.
Special responsibilities: Chair, Finance and Audit Committee; Investment Committee member

Professor Warwick Anderson AM

BS (Hons) UNE, PhD (Adelaide), DUniv (Adelaide), FAHA (Int), FRCPA (Hon), FAAHMS, DH (Newcastle)

Prof Anderson is Secretary-General of the International Human Frontier Science Program Organization. He was previously CEO of the NHMRC and a member of numerous international medical research bodies. Prof Anderson is a Vice-Chancellor’s Professorial Fellow at Monash University and has held academic and research positions at Monash University, The Baker Heart and Diabetes Institute, The University of Sydney and Harvard Medical School.

Mr Nigel Garrard

Mr Nigel Garrard BEcomm, AICD, CA FAMI

Mr Garrard has been the Managing Director and CEO of Orora Limited since 2013 when it was listed on the Australian Securities Exchange. Mr Garrard has held a number of senior executive positions including Managing Director of SPC Ardmona, Coca Cola Amatil’s food and service division, Chiquita Brands South Pacific Ltd and Amcor Australasia. He is a former Chair of the Australian Government’s National Food Industry Strategy Ltd and has been a director of a number of industry and not-for-profit organisations.
Special responsibilities: Chair, Hudson Foundation; Investment Committee member

Mr Andrew Leyden


Mr Leyden has been a Managing Director of Lazard Corporate Advisory and its predecessors since 2003. He has also worked for Credit Suisse Group, ANZ McCaughan Dyson and Arthur Andersen.
Special responsibilities: Chair, Investment Committee; Hudson Foundation Deputy Chair

Ms Zita Peach


Ms Peach is a non-executive director on ASX listed, government and not-for-profit boards. She has worked in senior leadership roles as Executive Vice-President and Managing Director of Fresenius Kabi, Vice-President of Business Development at CSL Limited and Commercial Director at Merck Sharp Dohme. Ms Peach has extensive experience in commercialising technologies, licensing, mergers and acquisitions. She is a graduate of the Australian Institute of Company Directors and a Fellow of the Australian Marketing Institute. She is a non-executive director of Starpharma Holdings Limited, AirXpanders Inc, Monash IVF Group Limited, Visioneering Technologies Inc, Pacific Smiles Group Ltd and Mt Buller, Mt Stirling Alpine Resorts Management Board.
Special responsibilities: Chair, Intellectual Property and Commercialisation Committee

Mr David Hanna 

BEc/BA/BAsian Studies, GAICD

Mr Hanna joined Monash University in 2012 as Director, Business Strategy. For 15 years prior to this, David held a variety of senior management positions in the Victorian Government in economic development policy, international policy and operations and innovation policy. Earlier, Mr Hanna spent 15 years in the Australian Government, including three years on the personal staff of then Prime Minister, Bob Hawke. He is a Chair of Docklands Studios Melbourne Pty Ltd and Amearo Engineering Pty Ltd, and a Director of Springvale Monash Legal Service Inc and Unimutual Ltd.

Professor Kim Cornish

BS (Hons), PhD (London)

Prof Cornish is Director of the Monash Institute of Cognitive and Clinical Neurosciences and the Head of School of Psychological Sciences. Prior to joining Monash University in 2009, she was a Canada Research Chair (Tier 1) at McGill University (Montréal, Canada). In 2017, Professor Cornish was elected Fellow of the Academy of the Social Sciences in Australia. Over her 25-year career, Professor Cornish has received over $9 million in competitive grant and fellowship funding for her work in delineating cognitive profiles and trajectories in typically developing children and in neurodevelopmental disorders. Professor Cornish is the co-inventor of TALI Train™ – a novel, interactive technology platform for detecting and training attention deficits in early childhood.

Board observer

Professor Erwin Loh


Prof Loh is Chief Medical Officer and Executive Director of Innovation, Patient Safety and Experience at Monash Health, Victoria’s largest health service. He has qualifications in medicine, law and management, and is a practising doctor and lawyer. He is fellow of the Royal Australasian College of Medical Administrators, Australasian College of Health Service Management, Australian Institute of Company Directors and Australasian College of Legal Medicine. He is on the board of Monash Health Research Precinct, Australasian College of Legal Medicine and Royal Australasian College of Medical Administrators. He is an adjunct Clinical Professor at Monash University where he teaches clinical leadership and health law. He has spoken at local and international conferences, supervises doctoral students, and has published articles, books and book chapters.

Company Secretary

Mr Rob Merriel

BA, Grad Dip (Psych), Grad Dip (Accounting), CPA

Mr Merriel is a Certified Practicing Accountant with more than 35 years working in medical research (Baker IDI and Hudson Institute), healthcare (Melbourne Health and Monash Health) and commercial organisations (Pacific Dunlop and Deloitte Consulting). The current Chief Financial Officer and Chief Commercialisation Officer of Hudson Institute, Mr Merriel is a Director of MHRP Pty Ltd and was previously the director and company secretary of several biotechnology-focused companies including BioGrid Australia, Biocomm, the Australian Technology Fund and Evivar.

Board committees

Finance and Audit Committee

This committee assists the board in internal control and compliance, accounting and financial reporting and risk management processes of Hudson Institute.
Members: Ms Maria Trinci (Chair since 2015), Ms Carmel Mortell and Secretary Mr Rob Merriel. Hudson Institute’s CEO, Professor Elizabeth Hartland, attends meetings of this board committee.

Investment Committee

This committee advises the board and director on the effectiveness of investment policies, and approves the engagement of investment managers and investment transactions.
Members: Mr Andrew Leyden (Chair since November 2016), Mr Nigel Garrard, Ms Maria Trinci and Secretary Mr Rob Merriel. Hudson Institute’s Financial Accountant, Mrs Jessie Wo, attends meetings of this board committee.

Intellectual Property and Commercialisation Committee

This committee advises the board and director on statutory requirements for corporate governance and commercialisation of Hudson Institute’s intellectual property and related issues.
Members: Mrs Zita Peach (Chair since August 2016), Mr Grant Fisher, Dr Michael Pannacio, Dr Andrew Gearing, Dr Rob Klupacs and Secretary Mr Rob Merriel. Hudson Institute’s CEO, Professor Elizabeth Hartland, attends meetings of this board committee.